ZD6474 (vandetanib)
Sponsors
Genzyme, a Sanofi Company, Sanofi, National Cancer Institute (NCI), University of Wisconsin, Madison
Conditions
Advanced Colorectal CarcinomaAnaplastic AstrocytomaAnaplastic Mixed OligoastrocytomaAnaplastic OligodendrogliomaCarcinoma, Non Small Cell LungGlioblastoma MultiformeGliosarcomaHead and Neck Cancer
Phase 1
Open Label, Phase I ZD6474 Head and Neck Cancer Study
CompletedNCT00450138
Start: 2006-12-31End: 2011-11-30Updated: 2016-08-29
Phase I FOLFOX Combination
CompletedNCT00499850
Start: 2005-08-31End: 2008-04-30Updated: 2016-08-25
Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases
TerminatedNCT00807170
Start: 2009-05-31End: 2010-08-31Updated: 2016-08-29
Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer
WithdrawnNCT01004419
Start: 2009-11-30End: 2011-05-31Updated: 2015-10-02
Phase 2
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
CompletedNCT00098345
Start: 2004-11-30End: 2017-04-19Updated: 2018-05-07
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
CompletedNCT00358956
Start: 2006-08-31End: 2014-05-31Updated: 2017-01-30
Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
CompletedNCT00659438
Start: 2008-02-29End: 2011-07-31Updated: 2016-12-05
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
CompletedNCT00995007
Start: 2009-09-30End: 2015-12-31Updated: 2016-03-29